Company intelligence / Profile preview

Amalyte Pharmaceuticals

San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

Amalyte Pharmaceuticals was a clinical-stage biotechnology company focused on developing therapies for metabolic and inflammatory diseases. The company's lead asset was MBX-2982, an oral, potent, and selective agonist of G protein-coupled receptor 119 (GPR119). Amalyte was specifically advancing MBX-2982 for its potential to prevent hypoglycemia in patients with type 1 diabetes by enhancing the secretion of glucagon-like peptide-1 (GLP-1) and other incretins. In October 2019, Amalyte was acquired by CymaBay Therapeutics, which sought to re-integrate MBX-2982 into its own clinical pipeline.

Therapeutic areas: Endocrinology
Modalities: Small molecule
Industry: Biotech

Partnerships

CymaBay Therapeutics

Beyond the preview

Go deeper on Amalyte Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amalyte Pharmaceuticals.

Explore the full profile